Keeogo™ can be used on patients with mobility impairment or endurance issues due to medical conditions, such as osteoarthritis of the knee, multiple sclerosis, Parkinson’s disease, stroke, and more. KeeogoTM may improve walking function, independence and quality of life by reducing pain, compensatory movement patterns and fatigue.
Keeogo™ provides additional strength and stability to help complete a movement only when initiated by the user and is contraindicated for patients with complete spinal cord injury.
Keeogo™ helps patients with:
B-Temia Inc. has a team of clinical specialists who will provide in depth training sessions as well as ongoing clinical and technical support, in addition to comprehensive manuals, to ensure the greatest level of success for clinicians using Keeogo™ with their patients.
Since 2010, Keeogo™ has been involved in field testing, product evaluations, and clinical trials. Over 125 participants have tested the device in more than 20 studies. These studies demonstrate how the KeeogoTM has the potential to:
For a greater, in-depth look at these potential benefits, consult the Keeogo™ Technical Summary document as provided.
The benefits of Keeogo™ are currently under investiation and have not yet been clinically proven. The intended functional and clinical benefits for individuals with mobility impairments wearing Keego™ on a regular basis include, but are not limited to, the following:
Keeogo™ has been used by multiple volunteers in contorlled and uncontrolled studies with multiple sclerosis, knee & hip osteoarthritis, Parkinson's disease and peripheral artery disease patient populations and the following collaborators:
B-TEMIA Inc. has initiated a multi-center pivotal clinical trial, aimed at demonstrating the superior clinical benefits and safety for home use of Keeogo™, for patients living with reduced mobility due to medical conditions. Led by Principal Investigator, Dr. Chris A. McGibbon, PhD, from the University of New Brunswick’s, Faculty of Kinesiology and Institute of Biomedical Engineering, the study is expected to generate the required data to support the submission of a 510(k) pre-market notification to the U.S. Food and Drug Administration in 2016, a prerequisite to start commercialization in the United States.
“This is the first international clinical trial involving the Dermoskeleton™ technology that aims at demonstrating the efficacy and safety of Keeogo™ during everyday community and home mobility use, something that has not been possible in the past with other exoskeleton technologies that were developed principally for use in a clinical rehabilitation setting”, stated Dr. Chris A. McGibbon.
As part of the trial, B-TEMIA has partnered with three of the most reputable rehabilitation institutions in North America: the Rehabilitation Institute of Chicago, the Spaulding Rehabilitation Hospital Boston, and the Toronto Rehabilitation Institute–UHN.
To learn more about how you or your patients may be involved in this clinical trial, contact firstname.lastname@example.org.